Immunogenicity of a trivalent influenza vaccine and persistence of induced immunity in adults aged ≥60 years in Taizhou City, Zhejiang Province, China, during the 2018–2019 season

References

• Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, et al. Influenza. Nat Rev Dis Primers. 2018;4:3. doi:10.1038/s41572-018-0002-y.
   PubMed Web of Science ®Google Scholar
• Gaitonde DY, Moore FC, Morgan MK. Influenza: diagnosis and treatment. Am Fam Physician. 2019;100:751–10.
   PubMed Web of Science ®Google Scholar
• Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, Cohen C, Gran JM, Schanzer D, Cowling BJ, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391:1285–300. doi:10.1016/S0140-6736(17)33293-2.
   PubMed Web of Science ®Google Scholar
• Smetana J, Chlibek R, Shaw J, Splino M, Prymula R. Influenza vaccination in the elderly. Hum Vaccines Immunother. 2018;14:540–49. doi:10.1080/21645515.2017.1343226.
   PubMed Web of Science ®Google Scholar
• Tamura S, Ainai A, Suzuki T, Kurata T, Hasegawa H. Intranasal inactivated influenza vaccines: a reasonable approach to improve the efficacy of influenza vaccine? Jpn J Infect Dis. 2016;69:165–79. doi:10.7883/yoken.JJID.2015.560.
   PubMed Web of Science ®Google Scholar
• National Immunization Advisory Committee Technical Working Group IVTWG. Technical guidelines for seasonal influenza vaccination in China (2021-2022). Zhonghua Liu Xing Bing Xue Za Zhi. 2021;42:1722–49. doi:10.3760/cma.j.cn112338-20210913-00732.
   PubMedGoogle Scholar
• Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine. 2011;29:5785–92. doi:10.1016/j.vaccine.2011.05.040.
   PubMed Web of Science ®Google Scholar
• Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Clin Infect Dis. 2008;46:1078–84. doi:10.1086/529197.
   PubMed Web of Science ®Google Scholar
• Narang V, Lu Y, Tan C, Camous XFN, Nyunt SZ, Carre C, Mok EWH, Wong G, Maurer-Stroh S, Abel B, et al. Influenza vaccine-induced antibody responses are not impaired by frailty in the community-dwelling elderly with natural influenza exposure. Front Immunol. 2018;9:2465. doi:10.3389/fimmu.2018.02465.
   PubMed Web of Science ®Google Scholar
• Young B, Zhao X, Cook AR, Parry CM, Wilder-Smith A, Ic MC. Do antibody responses to the influenza vaccine persist year-round in the elderly? a systematic review and meta-analysis. Vaccine. 2017;35:212–21. doi:10.1016/j.vaccine.2016.11.013.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Muscatello DJ, Wang Q, Yang P, Wu J, MacIntyre CR. Overview of influenza vaccination policy in Beijing, China: current status and future prospects. J Public Health Policy. 2017;38:366–79. doi:10.1057/s41271-017-0079-7.
   PubMed Web of Science ®Google Scholar
• Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, Li R-C, Xia S-L, Zhao Y-L, Li F-J, et al. Safety and immunogenicity of 2009 pandemic influenza a H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2010;375:56–66. doi:10.1016/S0140-6736(09)62003-1.
   PubMed Web of Science ®Google Scholar
• European Centre for Disease and Control (ECDC). AN, Tsolova S. ECDC, ed. Priority risk groups for influenza vaccination. 2008 [accessed 2017 Jul]. https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/0808_GUI_Priority_Risk_Groups_for_Influenza_Vaccination.pdf.
   Google Scholar
• Fleming DM, Elliot AJ. Estimating the risk population in relation to influenza vaccination policy. Vaccine. 2006;24:4378–85. doi:10.1016/j.vaccine.2006.02.053.
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis. 2008;197:490–502. doi:10.1086/524146.
   PubMed Web of Science ®Google Scholar
• Brydak LB, Machala M, Mysliwska J, Mysliwski A, Trzonkowski P. Immune response to influenza vaccination in an elderly population. J Clin Immunol. 2003;23:214–22. doi:10.1023/A:1023314029788.
   PubMed Web of Science ®Google Scholar
• Shu L, Zhang J, Huo X, Chen C, Fang S, Zong K, Guo Y, Zhao Y, Zhang J, Bao C, et al. Surveillance on the immune effectiveness of quadrivalent and trivalent split influenza vaccines — Shenzhen City and Changzhou City, China, 2018–2019. China CDC Wkly. 2020;2:370–75. doi:10.46234/ccdcw2020.095.
   PubMedGoogle Scholar
• Buxton JA, Skowronski DM, Ng H, Marion SA, Li Y, King A, Hockin J. Influenza revaccination of elderly travelers: antibody response to single influenza vaccination and revaccination at 12 weeks. J Infect Dis. 2001;184:188–91. doi:10.1086/322013.
   PubMed Web of Science ®Google Scholar
• Fan R, Huang X, Nian X, Ou Z, Zhou J, Zhang J, Zeng P, Zhao W, Deng J, Chen W, et al. Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study. Hum Vaccines Immunother. 2021;18:1–9. doi:10.1080/21645515.2021.1967041.
   PubMed Web of Science ®Google Scholar
• Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. 2013;31:770–76. doi:10.1016/j.vaccine.2012.11.074.
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24:1159–69. doi:10.1016/j.vaccine.2005.08.105.
   PubMed Web of Science ®Google Scholar
• Chahine EB. High-Dose inactivated influenza vaccine quadrivalent for older adults. Ann Pharmacother. 2021;55:89–97. doi:10.1177/1060028020935645.
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, et al. AS03-Adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis. 2013;13:485–96. doi:10.1016/S1473-3099(13)70046-X.
   PubMed Web of Science ®Google Scholar
• Roy S, Williams CM, Wijesundara DK, Furuya Y. Impact of pre-existing immunity to influenza on live-attenuated influenza vaccine (LAIV) immunogenicity. Vaccines (Basel). 2020;8(4):683. doi:10.3390/vaccines8040683.
   Web of Science ®Google Scholar
• Castilla J, Martinez-Baz I, Martinez-Artola V, Reina G, Pozo F, Garcia Cenoz M, et al. Decline in influenza vaccine effectiveness with time after vaccination, Navarre, Spain, season 2011/12. Euro Surveill. 2013;18(5):20388. doi:10.2807/ese.18.05.20388-en.
   Google Scholar
• Pebody R, Andrews N, McMenamin J, Durnall H, Ellis J, Thompson CI, Robertson C, Cottrell S, Smyth B, Zambon M, et al. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill. 2013;18. doi:10.2807/ese.18.05.20389-en.
   Google Scholar